HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MMV008138

inhibits apicoplast elongation; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Garg, Shilpi: 1 article (10/2018)
2.	Kochar, Sanjay Kumar: 1 article (10/2018)
3.	Pala, Zarna Rajeshkumar: 1 article (10/2018)
4.	Saggu, Gagandeep Singh: 1 article (10/2018)
5.	Saxena, Vishal: 1 article (10/2018)
6.	Butler, Joshua H: 1 article (01/2018)
7.	Carlier, Paul R: 1 article (01/2018)
8.	Casasanta, Michael A: 1 article (01/2018)
9.	Cassera, Maria Belen: 1 article (01/2018)
10.	Elahi, Rubayet: 1 article (01/2018)

Related Diseases

1.

04/10/2015 - "The Malaria Box compound, MMV008138, inhibits Plasmodium falciparum growth, and PfIspD has been proposed as a candidate intracellular target. "
10/30/2018 - "While few major components have already been studied from this pathway for their potential as a drug target, IspD (2-C-methyl-D-erythritol-4-phosphate cytidyltransferase) enzyme, the enzyme catalyzing the third step of the pathway has only been tested against a synthetic compound from Malaria box called MMV008138, which also has not shown adequate inhibitory activity against P. "
01/01/2018 - "Previously, we and others identified that the Malaria Box compound MMV008138 targets the apicoplast and that parasite growth inhibition by this compound can be reversed by supplementation of IPP. "

Related Drugs and Biologics

1.	Enzymes
2.	indolepropanol phosphate (IPP)